| Literature DB >> 35989496 |
Elham Mohammadisoleimani1, Zahra Firoozi2, Mohammad Mehdi Naghizadeh3, Ali Ghanbari Asad1, Babak Pezeshki3, Yousef Gholampour4, Ebrahim Mirzaei3, Mohamadhosain Simin5, Mahsa Saliani6, Ali Moravej7, Zolfaghar Armoon4, Yaser Mansoori2,3.
Abstract
BACKGROUND: SARS-CoV-2 is one of the most contagious viruses in the Coronaviridae (CoV) family, which has become a pandemic. The aim of this study is to understand more about the role of hsa_circ_0004812 in the SARS-CoV-2 related cytokine storm and its associated molecular mechanisms.Entities:
Keywords: SARS-CoV-2; cytokine storm; hsa-miR-1287-5p; hsa_circ_0004812; sponging effect
Mesh:
Substances:
Year: 2022 PMID: 35989496 PMCID: PMC9538103 DOI: 10.1002/jcla.24666
Source DB: PubMed Journal: J Clin Lab Anal ISSN: 0887-8013 Impact factor: 3.124
primers sequences
| Gene symbol (Gene name) | Primer sequence (5′–3′) |
|---|---|
| Hsa_circ_0004812 (F) | GAAGAAAATCAAAGCCTGGACTTC |
| Hsa_circ_0004812 (R) | GCTCAGCTCCTGGTGGTA |
| Hsa‐miR‐1287‐5p (F) | GCGTGCTGGATCAGTGGTT |
| Hsa‐miR‐1287‐5p (RT) | GTCGTATCCAGTGCAGGGTCCGAGGTA |
| TTCGCACTGGATACGACGACTCG | |
| hsa‐miR‐149‐5p and U48 (R) | GTGCAGGGTCCGAGGT |
| U48 (F) | AGGTAACTCTTGAGTGTGTCGCT |
| U48 (RT) | GTCGTATCCAGTGCAGGGTCCGAGGTA |
| TTCGCACTGGATACGACGGTCAGA | |
| RIG‐I (F) | ATGGGACGAAGCAGTATTTAG |
| RIG‐I (R) | GCTTGGGATGTGGTCTACTC |
| IL6R (F) | CCACTCCTGGAACTCATCTTTC |
| IL6R (R) | ACTCCTCCTGGGCACGAA |
| ACTB (F) | TGGAACGGTGAAGGTGACAG |
| ACTB (R) | CTGTAACAACGCATCTCATATTTGG |
Abbreviations: ACTB, actin beta; IL6R, interleukin 6 receptor; RIG‐I, RNA sensor RIG‐I; U48, SNORD48, small nucleolar RNA.
Participants' baseline and demographic information (p‐values 1: in comparison with negative control, 2: in comparison with asymptomatic COVID‐19)
| Negative control | Asymptomatic covid | Symptomatic covid |
| |||||
|---|---|---|---|---|---|---|---|---|
| Count | Column | Count | Column | Count | Column | |||
| Blood group | A+ | 12 | 26.1% | 12 | 26.1% | 11 | 23.9% | .355 |
| A− | 6 | 13.0% | 2 | 4.3% | 3 | 6.5% | ||
| B+ | 10 | 21.7% | 16 | 34.8% | 10 | 21.7% | ||
| B− | 0 | 0.0% | 5 | 10.9% | 3 | 6.5% | ||
| O+ | 11 | 23.9% | 8 | 17.4% | 12 | 26.1% | ||
| O− | 4 | 8.7% | 3 | 6.5% | 4 | 8.7% | ||
| AB+ | 3 | 6.5% | 0 | 0.0% | 3 | 6.5% | ||
| Sex | Male | 24 | 52.2% | 25 | 54.3% | 27 | 58.7% | .815 |
| Female | 22 | 47.8% | 21 | 45.7% | 19 | 41.3% | ||
| Underlying disease | None | 0 | 0.0% | 34 | 73.9% | 32 | 69.6% | .120 |
| Cardiovascular disease | 0 | 0.0% | 12 | 26.1% | 10 | 21.7% | ||
| Immune deficiency | 0 | 0.0% | 0 | 0.0% | 4 | 8.7% | ||
Features of symptomatic COVID‐19 patients
| Symptomatic covid | |||
|---|---|---|---|
| Count | Column | ||
| Underlying disease | None | 31 | 67.4% |
| Cardiovascular disease | 10 | 21.7% | |
| Immune deficiency | 5 | 10.9% | |
| Fever‐tremor | No | 21 | 45.7% |
| Yes | 25 | 54.3% | |
| cough | No | 17 | 37.0% |
| Yes | 29 | 63.0% | |
| Vomiting‐nausea | No | 36 | 78.3% |
| Yes | 10 | 21.7% | |
| stomachache | No | 26 | 56.5% |
| Yes | 20 | 43.5% | |
| dizziness | No | 33 | 71.7% |
| Yes | 13 | 28.3% | |
| headache | No | 21 | 45.7% |
| Yes | 25 | 54.3% | |
| sore throat | No | 23 | 50.0% |
| Yes | 23 | 50.0% | |
| BMI | ≤25 | 24 | 52.2% |
| 25–29 | 14 | 30.4% | |
| ≥30 | 8 | 17.4% | |
| fatigue | No | 27 | 58.7% |
| Yes | 19 | 41.3% | |
| diarrhea | No | 34 | 73.9% |
| Yes | 12 | 26.1% | |
Expression levels of hsa_circ_0004812, hsa‐miR‐1287‐5p, RIG‐I, and IL6R in asymptomatic and symptomatic COVID‐19 patients, and negative controls (p‐value computed from Kruskal–Wallis Test. p‐value 1: In comparison with negative control. p‐value 2: In comparison to asymptomatic covid)
| Gene name | Group |
| Mean | SD | Median |
|
|
|---|---|---|---|---|---|---|---|
| hsa_circ_0004812 | Negative control | 46 | 3.667 | 6.892 | 1.096 | ˂.001 | |
| Asymptomatic covid | 46 | 21.154 | 51.223 | 2.536 | .037 | ||
| Symptomatic covid | 46 | 46.431 | 62.662 | 26.719 | ˂.001 | ||
| hsa‐miR‐1287‐5p | Negative control | 46 | 2.811 | 5.895 | 1.011 | .246 | |
| Asymptomatic covid | 46 | 0.221 | 0.315 | 0.115 | ˂.001 | ||
| Symptomatic covid | 46 | 0.225 | 0.611 | 0.047 | ˂.001 | ||
| RIG1 | Negative control | 46 | 4.805 | 7.503 | 1.145 | .153 | |
| Asymptomatic covid | 46 | 50.362 | 68.598 | 23.595 | ˂.001 | ||
| Symptomatic covid | 46 | 121.466 | 113.529 | 88.392 | ˂.001 | ||
| IL6R | Negative control | 46 | 4.028 | 6.615 | 0.854 | .485 | |
| Asymptomatic covid | 46 | 15.514 | 19.057 | 7.105 | ˂.001 | ||
| Symptomatic covid | 46 | 20.332 | 17.129 | 18.700 | ˂.001 |
FIGURE 1Relative expression levels of hsa_circ_0004812, hsa‐miR‐1287‐5p, IL6R, and RIG‐I were shown in a box and whisker plot (10–90 percentile). (ns: p > .05; * p ≤ .05; *** p ˂ .001). (A) Upregulation of hsa_circ_0004812 in COVID‐19 patients compared with healthy. (B) Down expression of hsa‐miR‐1287‐5p in COVID‐19 patients compared with healthy controls. (C) Upregulation of RIG‐I in COVID‐19 patients compared with healthy controls. (D) Upregulation of IL6R in COVID‐19 patients compared with healthy controls.
FIGURE 2(A) LogFC heatmap of gene expression. (B) The negative correlation between hsa_circ_0004812 and hsa‐miR‐1287‐5p expression levels in COVID‐19 (r = −0.283, p value = .001). (C) The positive correlation between hsa_circ_0004812 and IL6R expression levels in COVID‐19 (r = 0.760, p value = ˂.001). (D) The positive correlation between hsa_circ_0004812 and RIG‐I expression levels in COVID‐19 (r = 0.236, p value = .005). (E) The negative correlation between hsa‐miR‐1287‐5p and IL6R expression levels in COVID‐19 (r = −0.234, p value = .006). (F) The negative correlation between hsa‐miR‐1287‐5p and RIG‐I expression levels in COVID‐19 (r = −0.514, p value = ˂.001).
FIGURE 3Overall workflow of bioinformatics analyses